Unassociated Document
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
______________________
 
FORM 8-K
 
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
March 22, 2012
Date of Report (Date of earliest event reported)
 
BOVIE MEDICAL CORPORATION
(Exact name of registrant as specified in its Charter)
 
 
 
Delaware
  
012183
  
11-2644611
(State or other jurisdiction
 of incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)
 
734 Walt Whitman Road, Melville, New York 11747
(Address of principal executive offices) (Zip Code)
 
(631) 421-5452
Registrant's telephone number, including area code
 
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 
 
 

Item 5.08. Shareholder Director Nominations.
 
At its meeting on March 22, 2012, the Board of Directors of Bovie Medical Corporation (the “Company”) approved July 12, 2012 as the date for the Company’s 2012 Annual Meeting of Stockholders (the “Annual Meeting”). The Board of Directors also approved May 21, 2012 as the record date for stockholders entitled to notice of and to vote at the Annual Meeting.  It is anticipated that the proxy materials will be mailed to stockholders on or about May 22, 2012.
 
Because the Annual Meeting will be held more than thirty (30) days from the calendar date of the Company’s 2011 Annual Meeting of Stockholders, the due dates for the provision of any qualified stockholder proposal or qualified stockholder nominations under the rules of the Securities Exchange Commission (the “SEC”) listed in the Company’s 2011 Proxy Statement on Schedule 14A as filed with the SEC on September 1, 2011, are no longer applicable. Such nominations or proposals, including any notice on Schedule 14N, are now due to the Company no later than May 1, 2012.

 
 
2
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Date: March 28,  2012
  
BOVIE MEDICAL CORPORATION
     
   
By:    /s/  Andrew Makrides
   
               Andrew Makrides
   
   Chief Executive Officer and
   Chairman of the Board
 

 
 
3